Trial reportPlastic and reconstructive surgery2026
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study.
Trial report in Plastic and reconstructive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOnabotulinumtoxinA (onabotA) treatment of prominent platysma muscles demonstrates a safety profile consistent with other onabotA aesthetic indications and effectively improves the appearance of vertical neck bands and jawline definition. The authors evaluated the safety and efficacy of repeat onabotA treatment for improving the appearance of moderate to severe platysma prominence.
methodsParticipants received up to 4 onabotA treatments administered a minimum of 3 months apart, including treatment with onabotA or placebo in the double-blind lead-in study.
resultsAll treatment-emergent adverse events related to study treatment were mild in severity with no observed trends across treatment cycles. Four participants reported 6 adverse events of special interest, including dysphagia (4 events) and facial paresis (2 events). All were mild in severity with no evidence of distant spread of toxin; almost all resolved by study end and none resulted in discontinuation. The percentages of participants achieving a one-grade or better improvement at maximum contraction on day 14 for each treatment cycle were 83.6%, 92.0%, 90.0%, and 98.0% as assessed by clinicians, and 82.5%, 90.4%, 87.0%, and 94.0% as assessed by participants.
conclusionRepeated onabotA treatment is well tolerated and improves platysma prominence over the course of multiple treatment cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.